



FOR IMMEDIATE RELEASE

CONTACT INFORMATION

Meredith Mannheim, Director of Operations
mmannheim@entegriion.com
Entegriion: 919-536-1500

ENTEGRION FORMS INTERNATIONAL VENTURE WITH LEADING EUROPEAN PRODUCER OF PATHOGEN-REDUCED PLASMA FOR TRANSFUSION

Research Triangle Park, NC, March 8, 2010 – Entegriion announced today that it has formed a manufacturing and development partnership with Kedrion S.p.A., headquartered in Barga in the Tuscany region of Italy. Kedrion will supply pathogen-reduced plasma from its newly updated manufacturing technology and dry the plasma using Entegriion’s proprietary spray-drying process. The resultant product, Resusix™, will be the basis for an new drug application (NDA) that Entegriion will submit to the FDA.

“This program is being funded by the U.S. Navy’s Office of Naval Research,” said Joe DaCorta, Entegriion’s Chief Technology Officer. “This technology is responsive to our military’s strong interest in breaking the cold chain dependency that limits the availability of the life saving benefits of plasma in remote areas of the world and to support far-forward battlefield operations.” Kedrion’s pathogen-reduced plasma has been marketed in Europe as a fresh-frozen plasma (FFP) that has shown remarkable benefits in terms of minimizing transfusion reactions as compared with blood-banked plasma. By incorporating Entegriion’s unique drying process, the resultant product will have the same outstanding clinical benefits but will also be capable of long-term storage and transport at ambient temperatures. The dried plasma is quickly rehydratable and transfusible, making it suitable for use in both hospital and difficult in-the-field environments.

“We are proud to have attracted such an outstanding manufacturing partner in Kedrion for this program,” said Stan Eskridge, Entegriion’s CEO. “This provides our company with additional technical expertise and creates a footprint in Europe that will enable both

companies to expand our work together as the relationship grows. We are also particularly proud of the confidence that the Office of Naval Research has placed in Entegriion with the award of this contract. It is a testament to the great work that our team continues to do to address critical clinical needs in both military and civilian medicine.”

About Entegriion

Entegriion is a life sciences company that selectively integrates synergistic technologies with those in its patent portfolio for development of novel devices and drugs that take advantage of the power of the vascular system to provide for hemorrhage control, hemodynamic balance, and active wound care. The company is based in North Carolina’s Research Triangle Park, and is the inventor of Stasilon® – the FDA-cleared, hemostatic and non-adherent medical textile technology approved for use both by prescription and by consumers from which multiple hemorrhage control products are made. Building on technologies licensed from the University of North Carolina, Entegriion’s portfolio includes platelet-derived as well as plasma-based platform technologies in addition to medical devices and diagnostic tools for real-time determination of the status of coagulation functionality. For more information, visit www.entegriion.com.

###